Evotec SE stock (DE0005664809): New AI leadership role highlights digital drug discovery push

Evotec SE has expanded its senior management team with a focus on digital and data-driven R&D, appointing Rui Wang as Executive Vice President, Head of Global In Silico and AI, a move announced on 06/02/2026 from Hamburg, Germany, according to an EQS-News release published via Deutsche Börse.

The Germany-based biotech, whose primary listing is on Xetra under the ticker EVT and whose American Depositary Shares trade on Nasdaq under the ticker EVO, said the newly created position is intended to accelerate the integration of computational science and AI technologies across its drug discovery platforms, as outlined in the company statement.

In its press communication, Evotec noted that Rui Wang will oversee the global in silico organization and AI strategy from the Manfred Eigen Campus in Hamburg, reporting into the existing R&D leadership, with the aim of enhancing target identification, molecular design, and translational decision-making workflows.

The appointment underscores the home-country importance of Evotec as a German life sciences group anchored in Hamburg, operating under BaFin supervision, and traded in euros on Xetra, where the stock remains a component of the German mid-cap biotech landscape.

On the U.S. side, Evotec's Nasdaq-listed shares closed at USD 2.95 on 06/02/2026, down 3.91% from USD 3.07 the prior trading day, according to MarketBeat price data as of that date, highlighting ongoing volatility in the name.

The stock move came on a day when the trading range on Nasdaq spanned intraday levels between approximately USD 2.88 and USD 2.95, per MarketBeat's quote summary for EVO as of 06/02/2026, indicating relatively modest intraday fluctuation despite the negative daily change.

While the latest management news was released in Germany through the EQS channel, the pricing dynamics on Nasdaq underline the dual exposure of Evotec to both its home market on Xetra and its U.S. investor base trading in USD.

The company did not combine the appointment news with any updated financial guidance or quantified cost-savings targets, positioning the change primarily as a strategic and organizational step to deepen its technological capabilities in drug discovery.

Evotec's IR contact in the EQS communication identified Hamburg as the corporate headquarters, confirming its German domicile and reinforcing the relevance of domestic sell-side coverage and regulatory oversight for investors tracking the stock.

In Germany, Evotec continues to trade actively on Xetra in EUR, offering local investors exposure to the company's contract research and co-owned pipeline business model through a liquid home-country venue.

As of: 06/03/2026

By the editorial team - specialized in equity coverage.

Evotec SE: core business model

Evotec operates as a partnership-focused drug discovery and development company that generates revenue primarily by running research programs for pharma and biotech clients and by sharing in the upside of jointly developed pipeline assets.

Evotec SE in peer comparison

Within the global contract research and discovery platform space, Evotec is often compared with CRO and discovery specialists such as WuXi AppTec and Charles River Laboratories, which likewise combine laboratory services with technology-enabled platforms for pharmaceutical clients.

WuXi AppTec, for example, reported revenue of RMB 44.6 billion for full-year 2024 in its March 2025 results release, while Charles River Laboratories indicated full-year 2024 revenue of USD 4.7 billion in a February 2025 filing, making both significantly larger in scale than Evotec but broadly exposed to similar outsourcing trends in R&D.

Conclusion

The appointment of Rui Wang as EVP, Head of Global In Silico and AI, highlights Evotec's strategic emphasis on embedding computational science and AI across its German-based drug discovery operations.

Set against a volatile share price on Nasdaq and a competitive peer group of larger CRO and discovery platform providers, the new leadership role is likely to be watched by investors for evidence that it can translate into more efficient R&D delivery and incremental high-value partnerships over time.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.